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ABSTRACT
Top1 inhibition by camptothecin (CPT) perturbs RNA
polymerase II (Pol II) density at promoters and along
transcribed genes suggesting an involvement of
Top1 in Pol II pausing. Here, we demonstrate that
Top1 inhibition favors Pol II escape from a
promoter-proximal pausing site of the human
HIF-1a gene in living cells. Interestingly, alternative
splicing at exon 11 was markedly altered in nascent
HIF-1a mRNAs, and chromatin structure was also
affected with enhanced histone acetylation and
reduced nucleosome density in a manner dependent
on cdk activity. Moreover, CPT increases transcrip-
tion of a novel long RNA (50aHIF1a), antisense to
human HIF-1a mRNA, and a known antisense RNA
at the 30-end of the gene, while decreasing mRNA
levels under normoxic and hypoxic conditions. The
effects require Top1, but are independent from
Top1-induced replicative DNA damage. Chromatin
RNA immunoprecipitation results showed that CPT
can activate antisense transcription mediated by
cyclin-dependent kinase (cdk) activity. Thus, Top1
inhibition can trigger a transcriptional stress,
involving antisense transcription and increased
chromatin accessibility, which is dependent on cdk
activity and deregulated Pol II pausing. A changed
balance of antisense transcripts and mRNAs may
then lead to altered regulation of HIF-1a activity in
human cancer cells.
INTRODUCTION
Human DNA topoisomerase I (Top1) regulate DNA
superhelicity during fundamental DNA transactions by
transiently cleaving and resealing DNA molecules (1,2).
Top1 is the sole target of camptothecin (CPT) and close
derivatives, which are anticancer drugs used in standard
therapy of human ovarian, small-cell lung, and colorectal
cancers (3). CPT interacts reversibly with its target pre-
venting strand relegation and increasing the half-life of
Top1-DNA cleavage complexes (Top1cc). A Top1cc can
become lethal when it collides with DNA replication
forks, leading to irreversible DNA breaks and the activa-
tion of S-phase checkpoint, G2 arrest and cell death (3).
Although the established cellular eﬀects of CPT are
peculiar of DNA damage responses, CPT inhibition of
Top1 occurs primarily in actively transcribed regions
(2,3). In contrast to the replication-dependent eﬀects, the
transcription-dependent eﬀects of Top1cc are not fully
understood.
Top1 is enriched in transcribed genomic regions as
established by Top1 DNA cleavage sites (1–3) and
chromatin immunoprecipitation (ChIP) (4). Top1 has
been shown to activate gene transcription, and to bind
to general transcription factors at promoters (5–7). A
broad and general inhibition of transcription elongation
is an immediate eﬀect of CPT in cultured cells (3,8), likely
due to the stalling of elongating RNA polymerases by
Top1ccs (3,8) and/or by persistent transcription-generated
DNA supercoils (9). Nevertheless, several groups have
reported more speciﬁc eﬀects at transcriptional levels for
CPT. For instance, CPT can activate the initiation step of
transcription (10) and the expression of selective genes in
*To whom correspondence should be addressed. Tel: +39 51 2094282; Fax: +39 51 2094283; Email: giovanni.capranico@unibo.it
Published online 23 October 2009 Nucleic Acids Research, 2010, Vol. 38, No. 1 159–171
doi:10.1093/nar/gkp817
 The Author(s) 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.human cells (11). In yeast, TOP1 gene deletion
preferentially up-regulates the expression of telomere-
proximal genes by increasing core histone acetylation
and chromatin accessibility (12).
Strikingly, CPT-induced Top1ccs have immediate and
speciﬁc eﬀects on RNA polymerase II (Pol II). CPT
triggers a high phosphorylation degree of the largest
subunit (Rpb1) of Pol II (4,13,14), showing an eﬀect on
a critical step of transcription regulation. Hyperphos-
phorylation occurs selectively on Ser-5 residues of the
conserved heptapeptide repeats of the carboxy-terminal
domain (CTD) possibly mediated by Cdk7, component
of TFIIH (13). Interestingly, a recent report showed that
CPT can disrupt the large inactive P-TEFb complex, thus
releasing a free active P-TEFb complex (containing the
Cdk9 subunit), which can then contribute to CPT-
increased phosphorylation of Pol II (15).
A second immediate eﬀect of CPT on Pol II has been
reported by us previously, and can be correlated to the
hyperphosphorylation of Rpb1 (4). Short cell treatments
with CPT induce a redistribution of chromatin-bound Pol
II along transcribed genes in human cancer cells, appar-
ently by enhancing the escape of Pol II from promoter-
proximal pausing sites. Remarkably, this early speciﬁc
CPT eﬀect is independent from replication and replicative
DNA damage (4). However, the release of Pol II from
pausing into elongation remained to be established.
Thus, to deﬁne the molecular mechanisms triggered by
Top1ccs at transcribing regions, we have here investigated
the CPT eﬀects at transcription and chromatin levels at the
hypoxia-inducible factor 1a (HIF-1a) gene locus in human
cancer cells. HIF-1a is a transcription factor and a master
regulator of the cell response to oxygen deprivation
(16,17), and a target of anti-angiogenesis and anticancer
agents (17). HIF-1a is subjected to post-translational reg-
ulation, as it is degraded at high oxygen tensions by an
oxygen-mediated hydroxylation of conserved prolyl and
asparaginyl residues, to which the von Hippel-Lindau
protein (pVHL) E3 ligase binds targeting HIF-1a to
proteasomal degradation (17). We selected to study the
HIF-1a gene because previous reports demonstrated that
CPT can markedly reduce HIF-1a protein accumulation in
hypoxic cells in a manner independent from the
hydroxylation pathway and from replicative DNA
damage promoted by CPT (18,19).
We here provide evidence that Top1ccs trigger the
escape of Pol II from promoter-proximal pause site of
the HIF-1a gene, activate a novel antisense transcript at
the 50-end of the HIF-1a locus and induce a more acces-
sible chromatin structure in a manner dependent on
cyclin-dependent kinase activity. Thus, Top1 inhibition
by CPT can result in a speciﬁc transcriptional stress lead-
ing to an imbalance of antisense and sense RNA ratios,
which may alter the regulation of cancer-relevant factors
such as HIF-1a.
MATERIALS AND METHODS
All methods and materials are fully described in the
Supplementary Data.
Cell lines and treatments
Human HCT116, HCT116(top1 siRNA) (20), MRCV
ﬁbroblast, and Jurkat cells were cultured with standard
techniques. Cells were maintained at 37 C in a humidiﬁed
incubator containing 5% CO2 in air (normoxic conditions,
20% O2). Hypoxia treatments were in a cell chamber with
1% O2 at 37 C. All drug treatments were performed
on exponentially growing cells at 37 C. In case of
co-treatments, cells were ﬁrst incubated with aphidicolin
(3mM) or DRB (50mM) for 15min, or caﬀeine (5mM) for
30min, and then, CPT was added to the medium for the
indicated time.
RNA puriﬁcation and primer-speciﬁc cDNA preparation
Total RNA was puriﬁed with the acid phenol method.
RNA pellets were resuspended in TE, and DNA was
digested with DNAse I. Total RNA (1mg) was used to
prepare cDNA using random primers and SuperScript
III (Invitrogen) as suggested by the manufacturer. When
speciﬁc primers were used for reverse transcription
with SuperScript III, conditions for the reaction were as
follows: 5min at 65 C and 50min at 55 C. Negative
controls were cDNAs prepared with no primer during
reverse transcription reactions.
Northern blotting
For Northern blot analysis, we used the procedures of
(21) with minor modiﬁcations. Strand-speciﬁc probe
was designed to be 40 nucleotides in length and was
synthesized by Intregrated DNA Technologies (IDT)
with the 30 StarFire extension (50-CAG CCC CAA TTC
TAA ATA AGC TCT TAG ATT TTC CTC AGC C/
NNNNNN/-30). The probe was then 30-end
32P-labeled
at high speciﬁc activity with the IDT StarFire kit (IDT)
using the manufacturer’s instructions. Hybridization was
performed for 16h in 7% SDS, 500mM sodium phos-
phate (pH 7.0), 1mM EDTA, 25% formamide at 42 C,
and then washed with 2  SSC, 0.5% SDS at 25 C for
20min.
The HIF-1a mRNA exon 2 was used as probe to deter-
mine the mRNA levels. Hybridization was performed for
16h in 7% SDS, 500mM sodium phosphate (pH 7.0),
1mM EDTA at 65 C. Final wash was at 65 C for 45min.
ChIP
The ChIP protocol and measurements of cDNA by
qrt-PCR were essentially as reported already (4). The
RNA-ChIP (RIP) method was as the ChIP protocol
with some modiﬁcations. Chromatin was fragmented to
an average size of 1000 nucleotides. Precipitated RNA
was extensively treated with DNase I, ethanol-precipitated
and treated again with DNase I. Then, cDNA was
prepared with random primers, and analyzed by qrt-
PCR. Negative controls were cDNA prepared with no
primers (NP), and non-retrotrascribed samples. At least
four dilutions of genomic DNA were run to generate the
standard curve. For all speciﬁc antibodies, the RNA
recovered values were at least 10-fold more enriched
than non-immune controls, and background levels set by
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values were at least 100-fold more enriched than non-
retrotranscribed samples.
RESULTS
CPT induces a reduction of Pol II at the HIF-1a gene
promoter in a Top1 and cdk-dependent manner
To investigate the escape of Pol II from pausing sites
induced by Top1ccs, we ﬁrst determined the presence of
a Pol II pausing site at the promoter of the HIF-1 gene
and the speciﬁcity of the CPT eﬀect in living cells by ChIP.
The human HIF-1a gene is 52.738-kb long and is
constituted of 15 exons. The intron size ranges from
0.084 to 4.8kb, with the exception of the ﬁrst intron,
which is 24.542kb (16) (Figure 1A). Experiments were
carried out with human control HCT116 colon cancer
cells and a HCT116 cell line with the Top1 gene silenced
by siRNA, which had Top1 contents reduced by  5-fold
as compared to parent HCT116 cells (20) (Figure 1E). The
results showed that Pol II accumulated at higher levels
at promoter-proximal sites in control cells (Figure 1B).
This is consistent with the polymerase pausing close to
the HIF-1 gene promoter. CPT reduced Pol II density
at promoters by 80-70% in HCT116 cells, whereas the
reduction was much less (25–30%) in HCT116-siTop1
cells (Figure 1B). While CPT abolished the diﬀerence in
polymerase density between the HIF-1 promoter and an
internal site in HCT116 cells, it did not in HCT116-siTop1
cells. Identical results were observed in other transcribed
genes such as GAPD (Figure 1B and data not shown).
The drug eﬀect is speciﬁc for Pol II as the general tran-
scription factor TBP was not aﬀected by CPT treatments
(Figure 1C). Thus, Pol II likely pauses at a promoter-
proximal site at the HIF-1 gene locus, and Top1 is
required for the speciﬁc reduction of Pol II density
induced by CPT.
To further evaluate the speciﬁcity of the CPT eﬀects, we
investigated two other DNA damaging agents, cisplatin
and VM-26, in comparison with CPT. The two agents
promote DNA damage that is independent from Top1
(22,23). The data show that Pol II density was decreased
even with the lowest CPT dose (0.4mM) at promoter-
proximal pausing sites of the studied genes (Figure 1D),
while it increased at sites around 2kb downstream to the
promoters (Figure 1D). In contrast, cisplatin and VM-26
decreased Pol II levels at both promoter and internal gene
sites at higher concentrations only (Figure 1D, and data
not shown). Thus, the ﬁndings further support that
the CPT-induced reduction of Pol II accumulation at the
promoters of HIF-1 and other genes likely requires
Top1ccs.
We then asked whether Cdk activity is needed for the
CPT eﬀect on Pol II accumulation at the promoter of the
HIF-1 gene. Cdk9 and Cdk7, which phosphorylate Pol II
to promote transcription elongation, are the main tar-
gets of 5,6-di-chloro-1-b-D-ribofuranosyl-benzimidazole
(DRB). We then determined if DRB could abolish the
CPT eﬀects. The results showed that CPT-induced redis-
tribution of Pol II along the HIF-1a and other transcribed
genes was abolished by DRB (Figure 1B), demonstrating
that Cdk activity is needed for the altered distribution of
Pol II along the studied genes induced by Top1cc.
Top1cc induces Pol II escape from the promoter-proximal
pausing sites
The above data suggest that Top1 may be involved in
Pol II pausing regulation and that Top1cc favors Pol II
escape. The pausing of elongating Pol II at promoter-
proximal sites can be a main mechanism of transcription
regulation (24). Interestingly, promoter-proximal pausing
can regulate the recruitment of further Pol II at the
promoter (25), and the coupling of mRNA maturation
to transcript elongation (26). Thus, it is critical to establish
whether Top1 inhibition by CPT can enhance Pol II
escape from promoter-proximal pausing sites. To this
end, we have determined the transcription levels down-
stream to the pausing site following drug treatments
in nascent HIF-1 mRNA. Nascent transcripts were
isolated with the RNA ChIP (RIP) method using Abs
against acetylated H4 histone or against the N-terminal
domain of Pol II large subunit.
The levels of chromatin-bound RNAs allowed us to
make several interesting observations. First, the levels of
chromatin-bound RNAs (Figure 2A) were at least 3-log
higher in the case of HIF-1 exonic regions than back-
ground (as established with samples retro-transcribed
without primers) and a-satellite DNA levels in cells
untreated and treated with CPT for 1h. In contrast,
HIF-1 gene intronic regions showed intermediate
levels of RNA recovery (about 1-log lower than exons,
Figure 2A). The observed diﬀerences among HIF-1
exons (Figure 2A) have been reported for other genes
already (27), and may be due to diﬀerences in ampliﬁca-
tion rates of primer sets. We have then measured the levels
of histone H4 acetylation across the entire gene by ChIP,
and the results showed that H4 acetylation was not
dramatically diverse among the studied fragments and
cannot explain the above diﬀerences in RNA recoveries
(Figure 2B). Thus, as intronic RNAs were lower than
exonic RNAs, our observations are consistent with
co-transcriptional splicing of HIF-1 mRNA (26).
Moreover, we noticed that levels of nascent RNA
recovery were not dramatically changed by CPT from
0.08 to 10 mM (Figure 2A), suggesting that Top1ccs do
not aﬀect the association of nascent transcripts with
chromatin. This is in agreement with the lack of inﬂuence
on transcription factories by immunoﬂuorescence micros-
copy (4).
We then determined the transcription levels down-
stream to the promoter-proximal pausing site of HIF-1
after Top 1 inhibition by CPT. As Pol II is known to
pause after 20–50 bases from start (25,26), and the ﬁrst
exon of HIF-1 is 319 bases long, we have compared
relative levels of transcription at three overlapping
regions spanning exon 1 and the exon 1/intron 1 border
(Figure 3A). The ﬁndings showed that CPT increased
transcription levels at the 30-end of exon 1 in a dose-
dependent manner, while the levels remained unchanged
at the 50-end (Figure 3B). Consistently with the ChIP data
Nucleic AcidsResearch, 2010, Vol.38,No. 1 161Figure 1. CPT-induced reduction of Pol II density at the HIF-1a gene promoter is dependent on Top1 and Cdk activity. (A) The human HIF-1a gene is
indicated with exons (boxes) and introns (lines). Red and green lines show sense and antisense transcripts. Black lines and numbers (distance from
mRNA start) indicate the amplicons used in this work. The lower map is not to scale. (B) HCT116 and HCT116(Top1-siRNA) cells were treated for
1h with CPT (10mM) and/or DRB (50mM). DNA recovery was determined at promoter-proximal (0.05 or 0 kb) and -distal regions (2.1 and 2kb) of
HIF-1a and GAPD genes. a-sat, control a-satellite DNA. Values are normalized to promoter-proximal regions in untreated cells, and are means±SD
of at least four determinations from two independent experiments. Mean recovery with non-immune IgG was 0.08. (C) TBP levels at promoters. Values
are means±SD of four determinations from two independent experiments. The dashed line shows recovery levels with non-immune IgG. (D) Eﬀects of
CPT, teniposide (VM26) and cis-platin (Cis-Pt) on Pol II density in human MRC5 cells at gene promoters (0kb), and internal gene regions (2 and
1.9kb). Values are normalized to untreated cells, and are means±SD of at least four determinations from two independent experiments. (E) Top1
content of HCT116(Top-siRNA) cells was about 20% of that of HCT116 cells by western blotting. b-Actin (b-ACT) is a loading control.
162 Nucleic Acids Research, 2010, Vol. 38,No. 1on Pol II (Figure 1B), DRB fully abolished the increase
of transcription levels induced by Top1ccs (Figure 3C).
In contrast, DRB did not aﬀect transcription levels at
the 50-end of exon 1 (Figure 3C), showing that CPT-
induced transcription downstream to the pause site was
dependent on Cdk9 and/or Cdk7 activity.
We also assessed CPT-induced transcription by
investigating the matured mRNA of the HIF-1 gene in
RIP samples. We found that CPT increased the transcrip-
tion levels of a region spanning exons 1 and 2 by using
Abs against acetylated histone H4 as well as against Pol II
(Figure 3D). The increase was not detected in total RNA
samples (input RNA in Figure 3D), showing that it was
present in the nascent RNA fraction only. As control, we
determined the levels of the matured mRNA further
downstream, in a region spanning exons 10–12. The
ﬁndings demonstrated that overall transcript levels were
not aﬀected by CPT (Figure 3D), even though the drug
markedly altered the splicing at this site as shown by the
presence of two additional bands (Figure 3D). Again, the
splicing alteration was readily observed in chromatin- and
Pol II-associated RNA fractions, but not in input RNAs
(Figure 3D).
To evaluate the generality of CPT eﬀects on Pol II
escape from pausing, we also determined transcription
levels downstream to the c-Myc gene P2 promoter
(Figure 4A). The P2 promoter is a well-known elongation
pausing site where Pol II density is higher than other gene
regions (4). Consistent with above data (Figure 2),
chromatin-associated RNA levels were about 10-fold
lower in intron 1 than exon 1 (data not shown).
Similarly to HIF-1 promoter, 1-h CPT treatments
increased transcription downstream to the c-Myc P2
promoter, and DRB fully abolished the CPT eﬀects
(Figure 4B). Increased transcription in RIP experiments
was detected both with Abs against Ac-H4 histone and
against Pol II large subunit (Figure 4B and C). Thus,
CPT-induced escape of Pol II was not speciﬁc for the
HIF-1 promoter, and may rather constitute a speciﬁc
response to CPT interference with transcription regulation
at several genes.
Our ﬁndings thus demonstrated that Top1cc can specif-
ically increase transcription elongation downstream to
the promoters of the HIF-1 and c-Myc genes. Similar
CPT-induced increases of 50-end transcription in RIP
experiments were reported for other human genes (28),
Figure 2. Levels of chromatin-associated RNAs at the HIF-1a gene locus. (A) HCT116 cells were treated for 1h with the indicated CPT
concentrations. RIP was performed with Abs against anti acetylated histone H4 (Ac-H4). Pelleted RNA was retrotranscribed with random
primers, and RNA recovery was determined with qRT-PCR using speciﬁc primers corresponding to the indicated regions along the HIF-1a gene,
a diagram of which (not in scale) is shown under the graph. The broken lines indicate average recovery of exonic, intronic and centromeric a-satellite
(a-sat) DNA regions. The background level was determined with cDNAs retrotranscribed without primers and was similar to a-sat recovery levels. A
representative experiment is shown: values are means±SD of three determinations. (B) Levels of Ac-H4 along the HIF-1a gene after 1-h CPT
treatments. ChIP was performed with either anti Ac-H4 or non-immune Abs. Values are normalized to exon 2, and are means±SD of four to six
determinations from two independent experiments.
Nucleic AcidsResearch, 2010, Vol.38,No. 1 163but the ﬁndings were not compared to the levels of Pol II
bound to their promoters. Our results also showed marked
splicing alterations in nascent mRNAs, demonstrating
that Top1cc can aﬀect co-transcriptionally the maturation
of HIF-1 mRNA.
Top1cc increases nascent transcripts in HIF-1a intergenic
and intron 1 regions in a manner dependent on
cyclin-dependent kinase activity
CPT-induced Top1cc can therefore aﬀect the transition of
Pol II to the elongation phase by enhancing Pol II escape
from the promoter-proximal pausing site. Pol II is known
to pause often along transcribed genes (9) and, in partic-
ular, Pol II density has a peak at mRNA termination
regions suggesting a pausing site (29). Thus, we next deter-
mined the levels of nascent RNAs at internal regions and
at 50- and 30-adjacent regions of the HIF-1 gene to inves-
tigate whether Top1cc may also alter Pol II pausing
regulation in the body of the gene. First, we noticed that
the RNA levels of intergenic regions upstream to the
promoter and downstream to the mRNA termination
site, were not at background levels, but rather they were
very similar to intron 1 levels (Figure 2A). Surprisingly,
the recovery of RNAs corresponding to 50- and 30-adjacent
regions were increased by 1-h treatments with CPT from
0.4 to 10mM (Figure 5A and B). We also found that CPT
increased the levels of RNAs corresponding to the 50-end
of the ﬁrst intron of HIF-1 gene, whereas the 30-end of
the ﬁrst intron and other internal gene regions were not
aﬀected (data not shown). In addition, DRB fully abol-
ished the increase of nascent RNAs at the HIF-1 gene
locus (Figure 5C), showing that the CPT-induced increase
of nascent RNA levels was dependent on Cdk activity.
Observations such as the increased nascent RNAs
upstream to the mRNA promoter cannot be easily
explained by alterations of Pol II pausing. Moreover,
the increase at the 30-end adjacent region of HIF-1a
mRNA was higher than at other regions (Figure 5B),
and could be due to CPT-induced alterations of mRNA
termination (30). However, we did not detect CPT-
induced increased RNA levels at this region when using
Figure 3. CPT-induced Top1ccs promote Pol II escape from the HIF-1a promoter pause site. (A) Diagram of the HIF-1a exon 1 region, with lines
indicating the studied amplicons. Numbers indicate positions from mRNA transcription start. (B) HCT 116 cells were treated for 1h with CPT, and
RIP was performed with anti-acetylated histone H4 Abs (Ac-H4). (C) CPT-induced transcription downstream to the pause site is dependent on Cdk
activity. On the right: PCR products of RIP samples. Controls are: genomic DNA (G), no reverse transcription (–RT) and water. a-satellite DNA (a-
sat) reactions show no genomic DNA contamination. A representative experiment is reported. (D) Top1cc eﬀects on transcription elongation and
alternative splicing of HIF-1a mRNA. Transcription levels at two downstream regions from the promoter pausing site spanning exons 1 and 2, and
exons 10 to 12. In the latter case, the observed extra band of 310 bases may correspond to a transcript in which exon 11 has been spliced out. –RT
indicates no retrotranscription. In all panels, RNA recovery values, normalized to exon 2 and control samples, are means±SD of at least four
determinations from two independent experiments.
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RNA was not associated with Pol II. Therefore, perturba-
tion of transcription termination was not the main reason
for the increase. As an antisense transcript (30aHIF-1a)
was known to be present at the 30-end of the HIF-1a
gene locus (31), the results suggested that CPT may
increase the levels of chromatin-associated 30aHIF-1a
RNA, and that the transcript was not transcribed by Pol
II. Thus, the ﬁndings raised the unexpected possibility that
Top1ccs induced by CPT could increase the transcription
of antisense, low-abundance transcripts.
Top1 inhibition by CPT increases the levels of a novel
antisense RNA at the 50-end of the HIF-1a gene locus
To assess whether CPT induced the transcription of the
30aHIF-1a antisense RNA, we performed PCR analyses
with speciﬁc primers in total cellular RNAs following CPT
treatments of HCT116 cells. We found that the antisense
transcript was indeed increased after 4h of CPT,
while HIF-1a mRNA levels were reduced (Figure 5A),
showing that Top1cc induced by CPT can increase the
levels of the 30aHIF-1a antisense RNA. This unexpected
ﬁnding prompted us to investigate whether CPT could
also activate antisense transcription at the 50-end of
the HIF-1a locus. cDNA prepared with strand-speciﬁc
primers (Figure 5B) demonstrated that antisense
transcripts were induced upon 4h of CPT treatments
spanning from an intronic region at about 8kb from the
mRNA start site to a region more than 0.5kb upstream to
the mRNA start (Figure 6B). PCR analyses in the second
half of the ﬁrst introns did not detect antisense transcrip-
tion (data not shown). Strand-speciﬁc cDNAs also showed
that the sense pre-mRNA, as detected at the exon 1 and an
intron 1 region, was not increased by CPT (Figure 6B).
No sense transcription was detected at a region 500bp
upstream to the mRNA promoter (Figure 6B).
The antisense RNA was then conﬁrmed with Northern
blots by using an oligonucleotide corresponding to the 2.1-
kb amplicon of intron 1 (Figure 6B) as strand-speciﬁc
probe. The novel antisense transcript (50aHIF1a)i s1 2
to 10kb long and increased over 4h of CPT treatments
(Figure 7A). No transcript was detected with an oligo-
nucleotide probe complementary to sense RNAs corre-
sponding to the same intronic region (data not shown).
We detected the 50aHIF1a transcript both under hypoxic
and normoxic conditions in a diﬀerent cell line, the
leukemic human Jurkat cells (Figure 7B), while, in agree-
ment with established knowledge (3), CPT decreased the
mRNA levels of HIF-1a mRNA under similar conditions
(Figure 7A).
Since collisions between Top1ccs and advancing DNA
polymerases can lead to irreversible DNA breaks at rep-
lication forks (3), we investigated whether the activation
of antisense transcription was dependent on Top1 and/or
replicative DNA damage. CPT stimulation of 50aHIF1a
RNA was dependent on Top1, as it was not signiﬁcantly
increased in HCT116(top1 siRNA) cells (Figure 7A).
Moreover, the drug eﬀect was independent from
replication-mediated DNA breaks and checkpoint
activation, as prevention of replicative DNA damage by
Figure 4. CPT-induced Top1ccs promote Pol II escape from the c-Myc P2 promoter. (A) Diagram of the studied c-Myc exon 1 region, with lines
indicating the studied amplicons. Numbers indicate positions from P2 transcription start. (B) CPT-induced transcription downstream to the P2 pause
site is dependent on Cdk activity. HCT116 cells were treated for 1h with CPT and/or DRB. RIP was performed with Ab against acH4 histone
(Ac-H4) or Pol II (Pol II). The gel shows PCR products of RIP samples. Controls are: genomic DNA (G), no reverse transcription (–RT) and water.
a-satellite DNA (a-sat) reactions show no genomic DNA contamination. A representative experiment is reported. (C) RIP was performed with Ab
against Pol II. All values are means±S.D. of four determinations from two independent experiments.
Nucleic AcidsResearch, 2010, Vol.38,No. 1 165aphidicolin, a DNA polymerase inhibitor, and of check-
point activation by caﬀeine, an inhibitor of mammalian
phosphatidylinositol 3-kinase family members (including
ATM and ATR), did not aﬀect antisense RNA activation
by Top1ccs (Figure 7C and D). Thus, CPT-induced
Top1cc increases the cellular levels of low-abundance
antisense transcripts (50aHIF1a and 30aHIF1a) while
reducing the mRNA of the human HIF-1a gene.
Top1 inhibition by CPT induces a more accessible
chromatin structure at later time
The present ﬁndings showed that Top1 inhibition by
CPT can interfere with speciﬁc transcription regulation
mechanisms involving Cdk activity and de-regulated
Pol II pausing at promoter-proximal sites leading to
the activation of antisense RNAs at the HIF-1a gene
locus. As antisense transcripts have been shown to
regulate chromatin structure, we next asked whether
histone modiﬁcations were also aﬀected by Top1cc. As
we did not detected any change of histone H4 acetylation
after 1h of drug treatments (Figure 2), we determined
core histone acetylation levels at later time points (2
and 4h) by ChIP in HCT116 cells (Figure 8). We
found that histone H4 acetylation at lysines 5, 8, 12
and 16 was increased at promoter and internal gene
regions after 4h, whereas it was substantially unmodiﬁed
upstream to the HIF-1 mRNA start site, and in satellite
Figure 5. Levels of speciﬁc nascent RNAs are increased by CPT-induced Top1ccs. HCT116 cells were treated for 1h with CPT and/or DRB as
indicated. Immunoprecipitated RNA was retrotranscribed with random primers, and measured with qRT-PCR. Levels of nascent RNAs at HIF-1a
gene locus by using Abs anti Pol II (Pol II) are shown in (A) or anti-acetylated histone H4 (Ac-H4) in (B). (C) Activation of nascent RNAs is
dependent on cdk activity as shown by RIP experiments performed with anti Ac-H4 Abs. On the right of (A) and (C), a representative gel of PCR
products. Samples are: genomic DNA (G), RIP samples (RT). –RT indicates no reverse transcription. a-sat amplicon shows no genomic DNA
contamination. In all panels, values are normalized to exon 2 (25kb) and control samples, and are means±SD of four to six determinations from
two independent experiments.
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had a tendency to be reduced by CPT at transcribed
regions of the studied genes (Figure 8C). H3 histone
acetylation was also increased, but such increases were
restricted to promoter regions (Figure 8B). As antisense
transcripts have been suggested to be a trigger for
heterochromatin formation and gene repression (32,33),
we determined the levels of histone H3K9 dimethylation,
a marker of heterochromatin, in cells treated with
CPT for 4h. We found that H3K9 dimethylation levels
were very low in the studied HIF-1a gene regions
in untreated cells and were not aﬀected by CPT
(Figure 8D). Co-treatments with DRB for 4h suppressed
the increase of histone acetylation by CPT (Figure 8E).
Thus, the ﬁndings showed that CPT also aﬀected histone
modiﬁcations at the HIF-1 gene locus, but at later time
points, promoting a more accessible chromatin structure
in a manner dependent on Cdk activity.
DISCUSSION
Even though CPT is commonly considered an eﬃcient
inhibitor of transcription elongation, the molecular mech-
anism has not been established fully. Here, we have
demonstrated that Top1cc has unexpected transcriptional
consequences: (i) increased Pol II escape from promoter-
proximal pausing sites of HIF-1 and c-Myc; (ii) increase
in non-coding antisense RNAs at the HIF-1 locus;
(iii) increase in chromatin accessibility; and (iv) marked
alteration of alternative splicing of HIF-1 mRNA. The
events require Top1 and are independent from replication
and replicative DNA damage. Interestingly, they are
not equal in time, as, for instance, (i) and (iv) occur
earlier while (iii) occurs later during drug treatments.
Remarkably, our ﬁndings also showed that inhibition of
Cdk9 and Cdk7 activity by DRB can suppress the CPT-
induced Pol II escape from promoter-proximal pausing
sites, activation of antisense transcription, and increased
chromatin accessibility. Even though we show evidence
that CPT may aﬀect several genes, the generality of the
drug eﬀects will deﬁnitively be addressed with a genome-
wide approach.
Previous reports showed that CPT promotes the
complete hyperphosphorylation of the Rpb1 of Pol II in
both primary and transformed cancer cells likely through
Cdk7 and/or Cdk9 activity (4,13–15). Thus, we propose
that Top1cc can increase the activity of Cdks that
phosphorylate Rpb1 promoting transcription elongation
at promoter-proximal pausing sites (Figure 9). Hyper-
phosphorylated Pol II is not competent for recruitment
to promoters leading to a reduction of Pol II density at
promoter regions of HIF-1, c-Myc (Figure 1) and other
genes (4). Interestingly, Pol II pausing at promoters has
recently been shown to favor the recruitment of further
Pol II at promoters (25), therefore Top1cc-induced Pol II
escape from the pause site may interfere with this mecha-
nism. Reduction of Pol II loading at the promoter will
eventually lead to decreased gene transcription.
A kinetic analysis of Pol II transcription at a gene-array
locus showed that transcription can be ineﬃcient and that
Pol II often pauses during elongation (9). Interestingly,
while leaving active the entire population of Pol IIs,
CPT increased the intragenic pausing eﬃciency but not
the pause time (9), resulting in a reduction of the elonga-
tion rate to a one-fourth of the normal rate. CPT does not
completely block transcription at the studied gene array,
in contrast to other inhibitors such as DRB (9). This is
consistent with our data showing that (i) CPT does not
destroy transcription factories under conditions in which
it destroys replication factories (4,34); (ii) 1-h CPT
treatments do not reduce the overall levels of chromatin-
associated RNAs along the HIF-1a gene locus (Figure 2);
and (iii) CPT readily alters alternative splicing at exon
10–12 site of HIF-1a, which implies that transcription
elongation is not abolished by CPT.
A striking ﬁnding of the present report is indeed the
demonstration that CPT-induced Top1ccs can aﬀect alter-
native splicing of HIF-1a mRNA co-transcriptionally
(Figure 3D). Recently, P-TEFb has been proposed to
play a critical role in coupling transcription elongation
Figure 6. Antisense transcription at the HIF-1a gene locus is increased
by Top1cc. Total RNA was extracted from cells untreated ( )o r
treated with 10mM CPT for 4h (+). (A) PCR analysis was performed
with primers as indicated in the map. (B) Upper panel: map of the
HIF-1a gene region analyzed (not to scale). Dashed lines show
the antisense transcript detected at the 50-end and the mRNA of the
HIF-1a gene. Arrows indicate speciﬁc primers used for retrotran-
scription: rv primers target the mRNA, and fw primers target antisense
transcripts. Black lines and numbers indicate regions analyzed by PCR.
Lower panel: PCR analyses on primer-speciﬁc cDNAs from HCT116
cells. Primers used for retrotranscription are indicated on top of the
gel, and amplicons used for PCR analyses are indicated on the left
of the gel. Negative and positive controls of retrotranscription were
no primers (NP) and random primers (N6), respectively. Negative
and positive controls of PCR were water (H2O) and genomic DNA
(G), respectively. a-satellite DNA (a-sat) shows no genomic DNA
contamination.
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DNA damage has been shown to alter alternative
splicing at several genes in human cells by increasing the
phosphorylation of Rpb1 of Pol II likely mediated by
P-TEFb (36). Two major mechanisms, not mutually exclu-
sive, may allow the coupling of transcription and alterna-
tive splicing: (i) recruitment of splicing factors to the
transcribing Pol II; and (ii) kinetic coupling involving
Pol II elongation rate (37). It has been shown that
UV-induced hyperphosphorylation of Pol II may cause a
lower elongation rate of Pol II, which may then aﬀect
alternative splicing (36). As Top1cc induced by CPT
readily triggers Rpb1 hyperphosphorylation (4,13–15)
and co-transcriptional alterations of HIF-1a alternative
splicing, our ﬁndings suggest that Top1ccs may inﬂuence
the elongation rate of Pol II with a similar mechanism as
proposed for UV-induced DNA damage (36).
Since increased Pol II escape and reduced elongation
rate are earlier CPT eﬀects, both of which may likely
be dependent on Cdk activation and Rpb1 hyperphos-
phorylation (Figures 3 and 4) (4,9), we propose that a
sustained CPT interference with Pol II regulation may
then lead to a more general disturbance of transcription
regulation (transcriptional stress) involving impaired
chromatin structure and activation/de-repression of
antisense transcription (Figure 9).
CPT-induced Pol II escape, cdk activation and
transcriptional stress can constitute a response to drug-
promoted Top1-mediated DNA breaks or to changed
duplex superhelicity due to inhibition of Top1 activity.
Interestingly, recent studies have shown that, when CPT
freezes a Top1cc, the enzyme catalytic cycle is hindered
with a more pronounced eﬀect on the removal of positive
supercoils (38). Consistently, the drug action results in the
inhibition of enzyme catalytic activity leading to a marked
torsional stress of the DNA template in living cells (38,39).
Upon siRNA knockdown of Top1 no eﬀect on Pol II
density was detected (Figure 1), however Top1 is not
completely eliminated from the studied cells. Moreover,
these cells are adapted to reduced Top1, therefore the
enzyme activity may be replaced by Top2 (2)
Local DNA torsional stress can signiﬁcantly regulate
gene expression in mammalian cells. Localized DNA
superhelicity can regulate the transcription of the human
c-Myc gene (40), and recently, the widespread divergent
transcription at protein-coding gene promoters has been
proposed to be determined by increased negative
supercoils generated by active transcription of mRNAs
(41). Therefore, Top1 inhibition by CPT may promote a
supercoiling imbalance locally at promoters, which may
then interfere with the regulation of Pol II pausing at
promoter-proximal sites. The precise mechanism remains
Figure 7. CPT activation of antisense transcription requires Top1 and is independent from replicative DNA damage. (A) Left panel: levels of
50aHIF1a antisense RNA in cells treated with 10mM CPT for the indicated time by northern blots. The probe was a 40-nt oligomer corresponding to
the 2kb amplicon and complementary to antisense RNA. Right panel: levels of HIF-1a mRNA in Jurkat cells treated with 10mM CPT by northern
blots of total RNAs with an exon 2 probe. Agarose staining was to check for equal RNA loading and integrity. (B) Increase of the 50aHIF-1a
transcript (2.1kb amplicon) in Jurkat cells treated with 10mM CPT in normoxia (20%) or hypoxia (1%). No DNA contamination was detected as
established with a-sat. A representative experiment is shown. (C) Total RNA was extracted from untreated cells or cells treated with 10mM CPT for
120min with or without aphidicolin (APH) or caﬀeine (Caﬀ). Left and right panels correspond to HCT116 and HCT116(top1-siRNA) cells,
respectively. In all graphs, RNA levels were normalized to mRNA exon 2 (25kb) and untreated samples, and the values are means±SD of four
determinations from two independent experiments. (D) Western blots of p53 and g-H2AX after CPT treatments of HCT116 cells with or without
Caﬀ or APH. Total cellular proteins (upper two panels) or histones (lower panels) were analyzed by western blots. CHK2 and H1 histone were used
as loading controls.
168 Nucleic Acids Research, 2010, Vol. 38,No. 1Figure 8. Late eﬀects of CPT on chromatin structure. (A) and (B) HCT116 cells were treated with 10mM CPT for 2 and 4h. ChIP was with Abs
against acetyl -K5,-K8,-K12 and K16 of histone H4 or acetyl –K9 and –K14 of histone H3. Histone acetylation levels were determined along the
HIF-1a gene, GAPD promoter (GAPD 0kb) and c-Myc P2 promoter (Myc  0.05kb). Mean DNA recovery with non-immune IgG was 0.41. Values
are means±SD of four to eight determinations from two to four independent experiments. (C) Levels of total histone H4 bound to chromatin. (D)
Levels of dimetil -K9 of histone H3 after CPT treatments. A representative ChIP experiment is shown, and values are means±SD of two to three
determinations. Mean DNA recovery with non-immune IgG is 0.59 (E) HCT116 cells were treated with CPT and/or DRB for 4h. Values are
means±SD of four to six determinations of two independent experiments. In all panels, the values are normalized to the recoveries of a-sat DNA,
as the internal standard, and to that of total histone H4 (shown in C).
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Cdk activity is coupled to torsional DNA tension and/or
nucleosome regulation. Thus, in addition to the well
known eﬀects on DNA replication and DNA damage
checkpoints, CPT can aﬀect transcription regulation
leading to alterations of gene expression patterns, which
may be relevant for cancer therapy, particularly at low
drug concentrations.
A main ﬁnding of the present report is that CPT can
lead to an impaired balance of cellular antisense and sense
transcripts which may inﬂuence the cancer-related HIF-1
pathway. HIF-1 is a heterodimer constituted by HIF-1a
or HIF-2a subunits, and a constitutively-expressed
HIF-1b subunit. The HIF-a subunits are regulated at
high oxygen tensions by the VHL pathway (17). Even
though the mechanism of CPT-induced reduction of
HIF-1a protein levels (18,19) remains to be deﬁned, our
ﬁndings show that the human HIF-1a gene locus is
complex as at least two non-coding RNAs are present in
the antisense orientation relative to the mRNA. An attrac-
tive hypothesis is that they may have a role in novel
mechanisms of transcriptional and/or post-transcriptional
regulation of HIF-1a activity (42,43), with an impact for
cancer prognosis and the development of new therapy for
human tumors.
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